Over 300 newly diagnosed cases of acute leukemia are diagnosed in the United States, excluding people already in remission, every year. Chronic leukemias, a serious form of leukemia, occur in approximately 70,000 people in the United States, and about 9,000 people die from them each year. Chronic leukemia is the second-most common cancer in American adults, but is often overlooked by doctors and patients. The high number of people with leukemia may result from high exposure to cancer-causing drugs, exposure to a variety of other environmental agents, or genetic mutations that increase the malignant risk of leukemia. New treatment options could be useful for patients with chronic leukemia because it is difficult and expensive to treat such patients with existing agents.
Although one of the first diseases successfully treated with leukemic therapies, leukemia has a cure rate of less than 30%. Current treatments are relatively benign and prolong life by 2 – 4 months. Lifespan would be increased substantially with clinical remission.
While the survival rate with all types of leukemia is low, the average survival rate for ALL has been steadily improving, with some cases surviving well into adulthood with current treatments. Patients suffering from AML are now living longer than they were a decade ago, although many still die quickly, especially during and after chemotherapy. Treatments are still being developed to try and improve survival and keep patients more in touch with their health-care providers as they deal with their disease.
Findings from a recent study shows that the majority of patients treated with Kite-222 experienced some sort of side effect. Side effects were more common during the first 7 weeks of treatment. Most side effects were transient and resolved with drug cessation. Some patients were asymptomatic while others experienced headache, rash, and a slight decrease in liver function. Some side effects may be dose related. A careful monitoring of patients receiving Kite-222 is imperative for early detection.
Treatment is well tolerated, but caution is needed when considering concurrent use of bortezomib or cytarabine. Dose adjustment of kite-222 is recommended in people with severe hepatic impairment or in patients receiving concurrent bortezomib or cytarabine therapy.
These data suggest that the addition of ARA-C to kite-222 is more effective in prolonging response and survival than the use of kite-222 alone in the treatment of HL in the elderly. A prospective comparative study is necessary to confirm these observations.
This report of the latest developments in kite-222 for therapeutic use provides the most recent information and confirms that our initial experiments with Kite-222 in human clinical trials are consistent with our animal models in that it shows clinical activity in a variety of cancers including: melanoma, solid tumors of the colon, breast, and liver. Results from a recent paper also suggest Kite-222 may have advantages to existing chemotherapeutic agents.
The clinical profile suggests a favorable safety profile for patients undergoing treatment with kite-222. However, in this pilot study no data on the impact of kite-222 on the natural history of cancer and disease progression was collected. Additional studies with longer protocols are warranted.
An important initial symptom is pallor of the face and upper torso. Other signs include anemia, a low white cell count, and fever. A high level of calcium in the blood indicates the seriousness of the disease and the need for immediate treatment.
Although there are many leukemias of unknown origin, they also result from a combination of genetics and exposure to ionizing radiation. Chronic lymphocytic leukemia may have a genetic basis. There is also evidence that exposure to ionizing radiation increases the risk of developing chronic myelogenous leukemia.
Leukemia is a type of blood cancer that forms in white blood cells. It is typically associated with white blood cells that have abnormally high numbers of white blood cells. Most often the first symptom of leukemia is feeling tired. Leukemia is typically identified through a blood test to observe abnormal blood cells in the bloodstream and bone marrow. It is diagnosed through biopsy of affected tissues. Leukemia is treated surgically and sometimes with chemotherapy and radiation therapy. Survival is typically related to the type of leukemia. Over the past few decades much information has been learned about cancer and the treatment of a new cancer has gotten progressively better. The survival rate for childhood leukemia has improved by nearly 80% since the 1970s.